Skip to content

Clinical application of cold plasma in the treatment of dermatophytosis: a prospective exploratory study

Clinical application of cold plasma in the treatment of dermatophytosis: a prospective exploratory study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095880
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-01-16
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dermatophytosis

Interventions

Cold plasma therapy group:After the patients completed the routine treatment, the cold plasma treatment system independently developed by Nanjing University of Aeronautics and Astronautic was used. Ea
Conventional treatment group:The standard treatment regimen was provided in the Chinese Guidelines for the Diagnosis and treatment of Tinea corporis and Tinea cruris (Primary Practice Edition 2022) an

Sponsors

General Hospital of Eastern Theater Command, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for tinea pedis and tinea cruris (at the same time meet the following 2 items) : 1) Typical clinical manifestations: the primary lesion was papules, blisters or papuloherpes, semi-annular erythema with clear boundary and obvious inflammation extending from the medial thigh to the outside, covered with scales, and subjective itching. 2) Positive fungal microscopic examination and/or dermatophytes isolated by culture; 2.Adult patients (18-70 years old). 3. All subjects voluntarily participated in the study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with tinea pedis and tinea cruris treated with antifungal agents within 1.2 weeks. 2. Patients with serious comorbidities, such as heart disease, diabetes, kidney disease, immune system disease, etc. 3. Patients with systemic infection or serious infection other than burn, such as pulmonary infection, urinary system infection, etc. 4. Patients with cognitive impairment or psychiatric disorders. 5. Those who plan to have children during or within 3 months after the trial (including male subjects). 6. Patients with difficulty in venous blood collection. 7. Systemic use of anti-HIV protease inhibitors and antineoplastic chemotherapy drugs, organ transplant immunosuppressants and glucocorticoids. 8. The patient is not cooperating with treatment.

Design outcomes

Primary

MeasureTime frame
Microscopic Examination of fungi;

Secondary

MeasureTime frame
Wound healing time;Systemic inflammatory response and changes in immune cells;

Countries

China

Contacts

Public ContactLi Weiqin

General Hospital of Eastern Theater Command, PLA

liweiqindr@nju.edu.cn+86 139 5183 9654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026